THC Global Group Ltd (ASX:THC) operates under a farm-to-pharma pharmaceutical model, now holding all three key cannabis licences being a Cannabis Research Licence, a Medicinal Cannabis Licence (Cultivation), and a Manufacture Licence.
The company has secured a significant cannabis growing capacity over multiple cultivation projects and owns a pharmaceuticals bio-manufacturing facility with attached testing and product development laboratory.
Bundaberg cannabis cultivation site manager John Hall. Photo credit: ABC Wide Bay, Kallee Buchanan
THC is in a prime position to commence medicinal cannabis production to service both domestic patients and the global export market.
The company is active globally with operations in Australia, New Zealand, and Canada and partnerships across Europe, Asia, and the Middle East.
In addition to its core Australian medicinal cannabis assets, THC has a significant Canadian presence – both in cannabis and in hydroponics equipment.
THC’s Canadian cannabis operation, Vertical Canna, holds property in Nova Scotia, Canada being developed into a large-scale cannabis production site.
The company’s hydroponics equipment division, Crystal Mountain, is a revenue generating manufacturer, wholesaler, and retailer of hydroponics equipment and supplies.